Medi Assist Ser.

Has Medi Assist Ser. declared dividend?

Medi Assist Healthcare Services Ltd has declared an 80% dividend, amounting to ₹4 per share, with an ex-date of September 6, 2024. However, the company's total returns have been negative in the short term, with a -16.97% return over the last 6 months and a -2.35% return over the past year.

Medi Assist Healthcare Services Ltd has declared an 80% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 80%<BR>- Amount per share: 4<BR>- Ex-date: 06 Sep 24<BR><BR>Dividend Yield: 0.81%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -16.97%, the dividend return was 0%, resulting in a total return of -16.97%.<BR><BR>Over the past year, the price return was -3.09%, the dividend return was 0.74%, leading to a total return of -2.35%.<BR><BR>For the 2-year period, there was no price return, no dividend return, and thus a total return of 0.0%.<BR><BR>In the 3-year period, the price return was 0%, the dividend return was 0%, resulting in a total return of 0.0%.<BR><BR>Over the last 4 years, the price return remained at 0%, with no dividend return, leading to a total return of 0.0%.<BR><BR>In the 5-year period, there was no price return, no dividend return, and therefore a total return of 0.0%.<BR><BR>Overall, while Medi Assist has declared a dividend, the total returns over various periods indicate a challenging performance, particularly in the short term, with significant negative price returns in the last 6 months and modest returns over the past year.

Who are the peers of the Medi Assist Ser.?

Medi Assist Ser.'s peers include Life Insurance, SBI Life, HDFC Life, ICICI Pru Life, ICICI Lombard, Max Financial, Go Digit General, New India Assura, and Star Health. Medi Assist Ser. has an average management risk and a 1-year return of 5.49%, while Max Financial leads with 62.33% and New India Assura lags at -22.35%.

Peers: The peers of Medi Assist Ser. are Life Insurance, SBI Life Insuran, HDFC Life Insur., ICICI Pru Life, ICICI Lombard, General Insuranc, Max Financial, Go Digit General, New India Assura, and Star Health Insu.<BR><BR>Quality Snapshot: Excellent management risk is observed at ICICI Lombard and Medi Assist Ser., while Average management risk is found at Life Insurance, SBI Life Insuran, HDFC Life Insur., ICICI Pru Life, General Insuranc, Max Financial, Go Digit General, and Star Health Insu, and the rest. Below Average management risk is noted at New India Assura. Growth is Excellent at Go Digit General, Average at SBI Life Insuran, HDFC Life Insur., ICICI Pru Life, ICICI Lombard, General Insuranc, Max Financial, Star Health Insu, and Medi Assist Ser., and Below Average at Life Insurance and New India Assura. All peers have Excellent capital structure except for New India Assura, which has Below Average.<BR><BR>Return Snapshot: Max Financial has the highest 1-year return at 62.33%, while New India Assura has the lowest at -22.35%. Medi Assist Ser. has a 1-year return of 5.49%, which is higher than New India Assura but lower than Max Financial. Additionally, the six-month return is negative for Medi Assist Ser., ICICI Pru Life, ICICI Lombard, General Insuranc, and New India Assura.

What does Medi Assist Ser. do?

Medi Assist Healthcare Services Ltd is a small-cap insurance company that provides healthcare services, with recent net sales of ₹1,889 Cr and a net profit of ₹215 Cr as of March 2025. It has a market cap of ₹3,968 Cr and key financial metrics include a P/E ratio of 43.00 and a return on equity of 16.79%.

Overview: <BR>Medi Assist Healthcare Services Ltd operates in the insurance industry and is categorized as a small-cap company.<BR><BR>History: <BR>The company was incorporated in 2000 as "Net Logistics Private Limited" and later changed its name to "Medi Assist Healthcare Services Private Limited" in 2012. It became a public company and adopted its current name in 2018. The latest quarterly results reported net sales and profit for March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 1,889 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 215 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 3,968 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 43.00 <BR>Industry P/E: 32 <BR>Dividend Yield: 0.71% <BR>Debt-Equity: 0.38 <BR>Return on Equity: 16.79% <BR>Price to Book: 7.34<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Who are the top shareholders of the Medi Assist Ser.?

The top shareholders of Medi Assist Ser. include mutual funds holding 25.12%, foreign institutional investors with 13.26%, and Bessemer India Capital Holdings II Ltd as the largest promoter with 15.68%. HDFC Large and Mid Cap Fund is the largest public shareholder at 7.79%, while individual investors hold 14.69%.

The top shareholders of Medi Assist Ser. include several key players. The majority of the shares are held by mutual funds, specifically through 13 schemes, which account for 25.12% of the total shares. The foreign institutional investors (FIIs) hold 13.26% through 46 different FIIs. <BR><BR>The promoter with the highest holding is Bessemer India Capital Holdings II Ltd, which owns 15.68% of the company. Among public shareholders, the HDFC Large and Mid Cap Fund is the largest, holding 7.79%. Additionally, individual investors collectively hold 14.69% of the shares.

How big is Medi Assist Ser.?

As of 24th July, Medi Assist Healthcare Services Ltd has a market capitalization of 3,909.00 Cr, with net sales of 723.32 Cr and a net profit of 90.88 Cr over the latest four quarters. Shareholder's funds are 471.74 Cr, and total assets are valued at 836.50 Cr.

As of 24th July, <BR><BR>Market Cap: Medi Assist Healthcare Services Ltd has a market capitalization of 3,909.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 723.32 Cr, while the sum of Net Profit for the same period is 90.88 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2024. Shareholder's Funds stand at 471.74 Cr, and Total Assets are valued at 836.50 Cr.

Is Medi Assist Ser. overvalued or undervalued?

As of November 6, 2025, Medi Assist Ser. is considered overvalued with a valuation grade of "expensive," reflected in its high PE ratio of 46.86 and underperformance of -11.59% year-to-date compared to the Sensex's gain of 6.62%.

As of 6 November 2025, the valuation grade for Medi Assist Ser. has moved from very expensive to expensive, indicating a slight shift in perception but still suggesting a high valuation. The company is currently considered overvalued based on its financial metrics. Key ratios include a PE ratio of 46.86, an EV to EBITDA ratio of 21.50, and a Price to Book Value of 0.66, which highlight the premium at which the stock is trading relative to its earnings and book value.<BR><BR>In comparison to peers, Medi Assist Ser. has a significantly higher PE ratio than Altius Telecom, which stands at 56.22, and a much lower EV to EBITDA ratio compared to Mindspace Business at 28.2. This suggests that while Medi Assist Ser. is expensive, its valuation is not as extreme as some of its peers. Additionally, the company's stock has underperformed relative to the Sensex, with a year-to-date return of -11.59% compared to the Sensex's gain of 6.62%, reinforcing the notion that the stock may be overvalued in the current market environment.

How has been the historical performance of Medi Assist Ser.?

Medi Assist Ser. has shown consistent growth over the past four years, with net sales increasing from 393.81 Cr in Mar'22 to 723.32 Cr in Mar'25, and profit after tax rising from 63.47 Cr to 91.60 Cr. The company also improved its cash flow significantly, reaching 138 Cr in Mar'25.

Answer:<BR>The historical performance of Medi Assist Ser. shows a consistent growth trajectory in key financial metrics over the past four years.<BR><BR>Breakdown:<BR>Medi Assist Ser. has demonstrated significant growth in net sales, increasing from 393.81 Cr in Mar'22 to 723.32 Cr in Mar'25. The total operating income followed a similar trend, rising from 393.81 Cr in Mar'22 to 723.32 Cr in Mar'25. Total expenditure, excluding depreciation, also increased from 302.59 Cr in Mar'22 to 569.21 Cr in Mar'25, with employee costs rising notably from 155.68 Cr to 305.86 Cr during the same period. Operating profit (PBDIT) grew from 91.22 Cr in Mar'22 to 177.87 Cr in Mar'25, reflecting a robust operating profit margin that slightly improved from 23.16% to 21.31%. Profit before tax increased from 80.69 Cr in Mar'22 to 111.79 Cr in Mar'25, while profit after tax rose from 63.47 Cr to 91.60 Cr. The consolidated net profit also saw an increase from 64.22 Cr in Mar'22 to 90.88 Cr in Mar'25, with earnings per share growing from 9.33 to 12.89. On the balance sheet, total assets rose from 592.71 Cr in Mar'22 to 1,144.57 Cr in Mar'25, alongside total liabilities increasing from 592.71 Cr to 1,144.57 Cr. Cash flow from operating activities improved significantly, reaching 138 Cr in Mar'25 compared to 64 Cr in Mar'22, while cash and cash equivalents at the end of Mar'25 stood at 83 Cr, up from 14 Cr in Mar'22. Overall, Medi Assist Ser. has shown strong financial performance with consistent growth in sales, profits, and cash flow over the years.

Is Medi Assist Ser. technically bullish or bearish?

As of December 2, 2025, Medi Assist Ser. shows a mildly bearish trend with a bearish MACD and Bollinger Bands, despite some daily bullish signals, and has significantly underperformed against the Sensex.

As of 2 December 2025, the technical trend for Medi Assist Ser. has changed from sideways to mildly bearish. The current stance is bearish with moderate strength. The weekly MACD is bearish, and both the weekly and monthly Bollinger Bands confirm a bearish outlook. The daily moving averages indicate a mildly bullish sentiment, but this is overshadowed by the overall bearish indicators. The stock has underperformed significantly against the Sensex over multiple time frames, further supporting the bearish sentiment.

When is the next results date for Medi Assist Healthcare Services Ltd?

The next results date for Medi Assist Healthcare Services Ltd is 09 May 2026.

The next results date for Medi Assist Healthcare Services Ltd is scheduled for 09 May 2026.

Are Medi Assist Healthcare Services Ltd latest results good or bad?

Medi Assist Healthcare Services Ltd's latest results show strong revenue growth and a significant profit increase, but declining operating margins and reliance on a tax reversal raise concerns about sustainability, leading to cautious investor sentiment. The stock has also underperformed in the market, indicating potential challenges ahead.

Medi Assist Healthcare Services Ltd's latest results present a mixed picture. On one hand, the company reported a significant net profit of ₹53.44 crore for Q4 FY26, which is a remarkable increase of 1,181.53% quarter-on-quarter. Additionally, the revenue growth of 28.13% year-on-year indicates strong topline momentum, reflecting the company's successful penetration in the health insurance intermediary space.<BR><BR>However, there are notable concerns. The operating margin has decreased from 21.57% to 19.94% year-on-year, primarily due to rising employee costs that have outpaced revenue growth. This deterioration in operational efficiency raises questions about the company's ability to maintain profitability amidst increasing costs.<BR><BR>Furthermore, despite the impressive profit figures, a significant portion of this profit was influenced by a tax reversal, which may not reflect the underlying operational health of the business. Without this one-time benefit, the normalized net profit would have been considerably lower, suggesting that the company faces ongoing challenges.<BR><BR>The stock has also underperformed over the past year, declining 12.83% compared to a smaller drop in the broader market, indicating investor skepticism about its growth sustainability. The technical outlook remains bearish, with the stock trading below major moving averages.<BR><BR>In summary, while the latest results show strong revenue growth and a substantial profit increase, the underlying margin pressures and operational challenges suggest caution for investors.

Should I buy, sell or hold Medi Assist Healthcare Services Ltd?

Which are the latest news on Medi Assist Ser.?

Why is Medi Assist Healthcare Services Ltd falling/rising?

As of 16-May, Medi Assist Healthcare Services Ltd's stock price is at 384.55, down 0.47%, with a concerning year-to-date decline of -16.35%. Despite recent positive financial results and strong institutional support, the stock's consistent underperformance and declining investor participation may prompt a sell recommendation.

As of 16-May, Medi Assist Healthcare Services Ltd is experiencing a slight decline in its stock price, currently at 384.55, reflecting a change of -1.8 (-0.47%). Despite this recent drop, the stock has shown some positive performance over the past week and month, with returns of +1.95% and +5.63% respectively, outperforming the Sensex, which has declined by -2.70% and -3.68% in the same periods.<BR><BR>However, the stock's year-to-date performance is concerning, with a significant decline of -16.35%, which is worse than the benchmark's -11.71%. Over the past year, the stock has generated a return of -19.94%, indicating a consistent underperformance against the benchmark indices. This underperformance is compounded by a falling investor participation, as evidenced by a 49.76% drop in delivery volume compared to the 5-day average.<BR><BR>On a more positive note, the company has recently declared strong results for March 2026, marking a turnaround after two consecutive negative quarters. Key financial metrics such as net sales and operating profit have reached their highest levels, which could indicate potential for recovery. Additionally, the company maintains a strong long-term fundamental strength with an average return on equity of 14.05% and high institutional holdings at 73.5%, suggesting confidence from larger investors.<BR><BR>Despite these strengths, the stock's consistent underperformance over the last three years and the recent decline in price may lead investors to view it as a sell, particularly given the negative sentiment reflected in the falling delivery volumes and overall market conditions.